| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
(R)-5,7-Dimethoxyflavanone targets inflammatory mediators, including nitric oxide (NO), TNF-α, and IL-12. By inhibiting these mediators, the compound exerts anti-inflammatory effects. The compound also has antimutagenic activity, as demonstrated in the Ames test. It is a flavanone with potential chemopreventive properties.
|
|---|---|
| ln Vitro |
In cell-free biochemical systems, (R)-5,7-Dimethoxyflavanone showed strong antimutagenic activity against MeIQ mutagenesis in the Ames test. The compound's antimutagenic activity is assessed using Salmonella Typhimurium strains TA100 and TA98. Its ability to inhibit inflammatory mediators can be evaluated in cell-based systems.
|
| ln Vivo |
In cell-based assays, (R)-5,7-Dimethoxyflavanone significantly and dose-dependently inhibits the inflammatory mediators nitric oxide (NO) and cytokines (TNF-α and IL-12). The compound's anti-inflammatory effects are evaluated in immune cells such as macrophages. It also showed strong antimutagenic activity in the Ames test.
|
| Enzyme Assay |
The cell-free assay for (R)-5,7-Dimethoxyflavanone involves the Ames test to assess antimutagenic activity. Salmonella Typhimurium strains TA100 and TA98 are used with MeIQ as the mutagen. The compound is tested at various concentrations to determine its ability to inhibit mutagenesis. The compound's ability to scavenge free radicals can be assessed using DPPH or ABTS assays.
|
| Cell Assay |
Cell-based assays for (R)-5,7-Dimethoxyflavanone involve culturing immune cells such as macrophages and treating them with the compound at concentrations ranging from 0.1 to 100 μM. Cells are stimulated with LPS to induce the production of inflammatory mediators. Nitric oxide (NO) levels are measured using the Griess assay. TNF-α and IL-12 levels in the supernatant are measured by ELISA.
|
| Animal Protocol |
There is no established animal experimental protocol for (R)-5,7-Dimethoxyflavanone specifically. As an anti-inflammatory and antimutagenic compound, it could potentially be evaluated in animal models of inflammation or mutagenesis. Typical studies involve administration of the compound to mice via oral or intraperitoneal routes. Inflammatory markers and DNA damage are assessed.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of (R)-5,7-Dimethoxyflavanone have not been extensively reported. As a small molecule with a molecular weight of 284.31 g/mol, the compound would be expected to have moderate oral bioavailability and tissue penetration. The compound is soluble in DMSO. Further pharmacokinetic studies would be required to determine plasma half-life, clearance, and metabolic pathways.
|
| Toxicity/Toxicokinetics |
(R)-5,7-Dimethoxyflavanone is intended for research use only and lacks established toxicity profiles for therapeutic applications. Standard laboratory safety precautions should be observed when handling this compound. As an anti-inflammatory compound, it may have effects on immune function. Standard toxicity studies in rodents would be required to determine the safety profile.
|
| References | |
| Additional Infomation |
(R)-5,7-Dimethoxyflavanone is a research-grade compound supplied for anti-inflammatory and antimutagenic research. It is not an approved pharmaceutical and has no clinical trial history. The compound is a flavanone with antimutagenic and anti-inflammatory activities. This product is intended for research use only and is not for human therapeutic applications.
|
| Molecular Formula |
C17H16O4
|
|---|---|
| Molecular Weight |
284.31
|
| Exact Mass |
284.105
|
| CAS # |
1277188-85-8
|
| PubChem CID |
689012
|
| Appearance |
White to off-white solid powder
|
| LogP |
3.41
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
21
|
| Complexity |
364
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
O1C2C=C(C=C(C=2C(C[C@@H]1C1C=CC=CC=1)=O)OC)OC
|
| InChi Key |
IAFBOKYTDSDNHV-CQSZACIVSA-N
|
| InChi Code |
InChI=1S/C17H16O4/c1-19-12-8-15(20-2)17-13(18)10-14(21-16(17)9-12)11-6-4-3-5-7-11/h3-9,14H,10H2,1-2H3/t14-/m1/s1
|
| Chemical Name |
(2R)-5,7-dimethoxy-2-phenyl-2,3-dihydrochromen-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.5173 mL | 17.5864 mL | 35.1729 mL | |
| 5 mM | 0.7035 mL | 3.5173 mL | 7.0346 mL | |
| 10 mM | 0.3517 mL | 1.7586 mL | 3.5173 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
